Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.

V. N. Acharya, D. K. Sinha, A. F. Almeida, A. V. Pathare

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95% of the patients.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalJournal of Association of Physicians of India
Volume43
Issue number8
Publication statusPublished - Aug 1995

Fingerprint

Erythropoietin
Renal Dialysis
Anemia
Ferritins
Chronic Kidney Failure
Dialysis
Iron
Quality of Life
Reticulocyte Count
Hematologic Tests
Serum
Bone Marrow
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. / Acharya, V. N.; Sinha, D. K.; Almeida, A. F.; Pathare, A. V.

In: Journal of Association of Physicians of India, Vol. 43, No. 8, 08.1995, p. 539-542.

Research output: Contribution to journalArticle

@article{73137af2a38149d2b190aeedd900aa85,
title = "Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.",
abstract = "The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95{\%} of the patients.",
author = "Acharya, {V. N.} and Sinha, {D. K.} and Almeida, {A. F.} and Pathare, {A. V.}",
year = "1995",
month = "8",
language = "English",
volume = "43",
pages = "539--542",
journal = "The Journal of the Association of Physicians of India",
issn = "0004-5772",
publisher = "Journal of Association of Physicians of India",
number = "8",

}

TY - JOUR

T1 - Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.

AU - Acharya, V. N.

AU - Sinha, D. K.

AU - Almeida, A. F.

AU - Pathare, A. V.

PY - 1995/8

Y1 - 1995/8

N2 - The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95% of the patients.

AB - The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95% of the patients.

UR - http://www.scopus.com/inward/record.url?scp=0029348847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029348847&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 539

EP - 542

JO - The Journal of the Association of Physicians of India

JF - The Journal of the Association of Physicians of India

SN - 0004-5772

IS - 8

ER -